Sequencing Therapies for Relapsed Refractory Multiple Myeloma: Bispecifics or CAR T-cell Therapy

Opinion
Video

Panelists discuss how to optimize the sequencing of bispecific antibodies and CAR T-cell therapies in relapsed/refractory multiple myeloma, considering factors such as patient characteristics, disease burden, and the unique advantages of each approach to maximize treatment efficacy and patient outcomes.

CN24_FO_MM_Seg07_Sequencing-Bispecifics
Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Related Content